Business Context and Reporting Period
This Form 8-K, dated December 27, 2024, reports on Tuhura Biosciences, Inc. (formerly Kintara Therapeutics, Inc.), a Nevada corporation. The filing addresses corporate governance changes resulting from a merger completed on October 18, 2024, wherein Kintara Therapeutics, Inc. merged with TuHURA Delaware. Following the merger, the surviving entity adopted the name TuHura Biosciences, Inc. and trades under the symbol HURA on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report regarding a change in certifying accountants and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for the reporting period. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Accountant Dismissal: Marcum LLP, the independent registered public accounting firm for the predecessor entity (Kintara), was dismissed effective December 31, 2024, following the merger completion.
- Accountant Appointment: Cherry Bekaert LLP, the former auditor for TuHURA Delaware, was appointed as the new independent registered public accounting firm for the Company for the fiscal year ended December 31, 2024.
- Corporate Name Change: The registrant officially changed its name from Kintara Therapeutics, Inc. to TuHura Biosciences, Inc.
Management Commentary, Risks, and Contingencies
Audit Committee Approval: The decision to dismiss Marcum and appoint Cherry Bekaert was unanimously approved by the Audit Committee of the Board of Directors on December 27, 2024.
Historical Audit Opinions: Marcum's reports for Kintara's fiscal years ended June 30, 2024, and 2023 did not contain adverse opinions or disclaimers. However, these reports included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
Disagreements and Reportable Events: The Company reported no disagreements with Marcum on accounting principles, practices, or auditing scope during the two most recent fiscal years or the subsequent period. Similarly, no reportable events occurred during this timeframe. TuHURA Delaware did not consult with Cherry Bekaert on matters requiring disclosure under Item 304(a)(2) prior to the appointment.
Investor Verification Checklist
- Verify the status of the "going concern" warning previously issued by Marcum LLP and whether the merger has resolved liquidity concerns.
- Confirm the transition timeline for Cherry Bekaert LLP to assume full audit responsibilities for the fiscal year ending December 31, 2024.
- Review the letter from Marcum LLP (Exhibit 16.1) to ensure there are no undisclosed disagreements regarding the dismissal.
- Monitor upcoming filings for the first financial statements prepared under the new corporate structure and auditor.